Abiopharma

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

Final approval of ANDA #ANDA #217216 for EVEROLIMUS. Decision date: 01/09/2026

Final approval of ANDA #ANDA #218188 for FUROSEMIDE. Decision date: 01/08/2026

Final approval of ANDA #ANDA #219511 for SAPROPTERIN DIHYDROCHLORIDE. Decision date: 01/08/2026

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Heery Christopher 🟡 adjusted position in 6.9K shares of Arcellx, Inc. (ACLX) at $64.15 Transaction Date: Jan 12, 2026 | Filing ID: 010889

📋 Panacea Innovation Ltd (10% Stockholder) plans to sell 40K shares of Atara Biotherapeutics, Inc. (at $5.88 each, total $235K) Filed: Jan 12, 2026 | ID: 010883

Director Kumar Neil 🔴 sold 80.0K shares of BridgeBio Pharma, Inc. (BBIO) at $78.19 ($6.0M) Transaction Date: Jan 08, 2026 | Filing ID: 000026

Smith Jeffrey T L 🟡 adjusted position in 9.3K shares (1 derivative) of Zymeworks Inc. (ZYME) at $22.67 Transaction Date: Jan 12, 2026 | Filing ID: 010865

Ciongoli Gregory Austin 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010864

Neu Kelvin 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010860

Landry Robert E 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010859

Cesano Alessandra 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010856

Director Schochet Barry P. 🟢 acquired 2.4K shares of Enhabit, Inc. (EHAB) at $9.97 Transaction Date: Jan 10, 2026 | Filing ID: 000002

Campoy Carlos 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010852